Cover Image
市場調查報告書

PharmaPoint:氣喘 - 現在/未來的主要企業

PharmaPoint: Asthma - Current and Future Players

出版商 GlobalData 商品編碼 314733
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:氣喘 - 現在/未來的主要企業 PharmaPoint: Asthma - Current and Future Players
出版日期: 2014年08月31日 內容資訊: 英文 55 Pages
簡介

本報告提供急速成長的氣喘治療藥市場相關研究,以包含新加入廠商的競爭情形為焦點,提供您主要企業相關最新資訊的系統性資訊。

第1章 目錄

第2章 簡介

第3章 市場預測

  • 全球市場
    • 預測
    • 推動因素與阻礙 - 全球問題點

第4章 現在/未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • GlaxoSmithKline
    • Merck & Co.
    • AstraZeneca/MedImmune
    • Novartis
    • Roche/Genentech
    • Teva
    • Boehringer Ingelheim

第5章 附錄

圖表

目錄

GlobalData has released its pharma report, "PharmaPoint: Asthma - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Asthma Market. The report identifies and analyses the key companies shaping and driving the global Asthma market. The report provides insight into the competitive Asthma landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Asthma
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of Asthma sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving Asthma market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Asthma market landscape Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. GlaxoSmithKline
    • 4.3.2. Merck & Co.
    • 4.3.3. AstraZeneca/MedImmune
    • 4.3.4. Novartis
    • 4.3.5. Roche/Genentech
    • 4.3.6. Teva
    • 4.3.7. Boehringer Ingelheim

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Diagnosed Asthma Patients
    • 5.4.2. Percent Drug-Treated Patients
    • 5.4.3. General Pricing Assumptions
    • 5.4.4. Generic Erosion
  • 5.5. Physicians and Specialists Included in This Study
  • 5.6. About the Authors
    • 5.6.1. Author
    • 5.6.2. Author/Reviewer
    • 5.6.3. Reviewer
    • 5.6.4. Global Head of Healthcare
  • 5.7. About GlobalData
  • 5.8. Disclaimer

List of Tables

  • Table 1: Global Sales Forecast ($m) for Asthma, 2013-2023
  • Table 2: Global Asthma Market - Drivers and Barriers, 2014
  • Table 3: Key Companies in the Asthma Market, 2014
  • Table 4: GSK's Asthma Portfolio Assessment, 2014
  • Table 5: GSK SWOT Analysis, 2013
  • Table 6: Merck's Asthma Portfolio Assessment, 2014
  • Table 7: Merck SWOT Analysis, 2012
  • Table 8: AstraZeneca's Portfolio Assessment, 2014
  • Table 9: AstraZeneca SWOT Analysis, 2014
  • Table 10: Novartis' Asthma Portfolio Assessment, 2014
  • Table 11: Novartis SWOT Analysis, 2012
  • Table 12: Roche/Genentech's Portfolio Assessment, 2014
  • Table 13: Roche/Genentech SWOT Analysis, 2014
  • Table 14: Teva's Portfolio Assessment, 2014
  • Table 15: Teva SWOT Analysis, 2014
  • Table 16: Boehringer Ingelheim's Portfolio Assessment, 2014
  • Table 17: Boehringer Ingelheim SWOT Analysis, 2014
  • Table 18: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Global Sales for Asthma by Region, 2013-2023
  • Figure 2: Company Portfolio Gap Analysis in Asthma, 2013-2023
Back to Top